ERRATUM TO ODAC BRIEFING DOCUMENT

FOR THE SEPTEMBER 23, 2022

US FDA ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING

NDA 211155

DUVELISIB

SECURA BIO, INC.

DATE RELEASED: SEPTEMBER 14, 2022

Secura Bio, Inc.

1995 Village Center Cir, Suite 128
Las Vegas, NV 89134-6360

Erratum to ODAC Briefing Document
ODAC Meeting
September 23, 2022

This document contains an erratum to the ODAC Briefing Document. The erroneous text is followed by the correction in bold below.

1. Page 53, Figure 16, At risk numbers below:

Figure 16: Overall Survival at Final Analysis (Prespecified Refractory Patient Subgroup[a])



Abbreviations: CI = confidence interval; HR = hazard ratio; MST = mean survival time.
[a] Refractory patients were defined in the DUO protocol as progressing <12 months after purine analog-based therapy (fludarabine/pentostatin).
Source: Sponsor Analysis

Corrected to read as:

Figure 16: Overall Survival at Final Analysis (Prespecified Refractory Patient Subgroup[a])



Abbreviations: CI = confidence interval; HR = hazard ratio; MST = mean survival time.
[a] Refractory patients were defined in the DUO protocol as progressing <12 months after purine analog-based therapy (fludarabine/pentostatin).
Source: Sponsor Analysis